Targeting tumor angiogenesis with gene therapy

Molecular Genetics and Metabolism

Volumn 74, Issue 1-2, 2001, Pages 120-127

  Chen, Qing Rong ^a   Zhang, Lei ^a   Gasper, Warren ^a   Mixson, A James ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Angiopoietin 2; Antiangiogenesis; Electroporation; Endothelial cells; Gene therapy; Nonviral; Tumor; VEGF; VEGFR2; Viral

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; CYTOKINE; ENDOSTATIN; PROTEIN P53; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN;

ANGIOGENESIS; CANCER THERAPY; ELECTROPORATION; GENE TARGETING; GENE THERAPY; PRIORITY JOURNAL; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

EID: 0034793083     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.2001.3223     Document Type: Article

References (64)

1. Cell biology of endothelial cells
2. Review article: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
3. Tumor angiogenesis: Therapeutic implications
4. The vasculization of tumors
5. Antiangiogenic gene therapy
6. Angiostatin induces and sustains dormancy of human primary tumors in mice
7. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
8. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents
9. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
10. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
11. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
12. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
13. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
14. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
15. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice
16. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene
17. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2
18. Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas
19. Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells
20. Angiozyme: A novel angiogenesis inhibitor
21. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
22. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms
23. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice
24. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4
25. Inhibition of angiogenesis in vivo by interleukin 12
26. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
27. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12
28. Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases
29. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12
30. Endostatin proteins binds tropomyosin: Potential for modulation of the anti-angiogenic activity of Endostatin protein
31. Angiostatin binds ATP synthase on the surface of human endothelial cells
32. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases
33. Systemic gene delivery expands the repertoire of effective antiangiogenic agents
34. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas
35. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice
36. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach
37. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases
38. Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific anti-tumor activity and acute dose-dependent toxicity in mice
39. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice
40. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
41. Alpha v integrins as receptors for tumor targeting by circulating ligands
42. A novel strategy for the tumor angiogenesis-targeted gene therapy: Generation of angiostatin from endogenous plasminogen by protease gene transfer
43. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
44. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity
45. Adenovirus- mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer
46. Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo
47. Systemic gene therapy with p53 reduces growth and metastases of a maligangt human breast cancer in nude mice
48. Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival
49. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts
50. Antiangiogenic therapy
51. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
52. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung, and breast carcinoma
53. Peptides derived from two separate domains of the matrix protein thrombospondin I have anti-angiogenic activity
54. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1
55. Transfection of thrombospondin I complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis
56. Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo
57. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis
58. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3
59. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis
60. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth
61. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis
62. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells
63. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine
64. Genes expressed in human tumor endothelium